Green dye could replace radioactive tracers in breast cancer lymph node checks

NCT ID NCT06085274

Recruiting now Diagnosis Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a green dye called indocyanine green (ICG) can accurately find cancer that has spread to lymph nodes in breast cancer patients who have already had chemotherapy. About 100 adults will receive the dye along with standard methods during surgery. The goal is to see if ICG is as good as or better than current techniques, with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Indocyanine green (ICG) dye
What this could lead to: If successful, this could offer a safer, simpler way to check for cancer spread in lymph nodes after chemotherapy, reducing the need for radioactive tracers.
What could go wrong: This is a small, early-phase trial (100 people) testing accuracy, not a treatment. The dye may not work as well as standard methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

University Health Network
RECRUITING

Toronto, Ontario, M5G2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.